Nature Communications (Feb 2024)

Regulatory T cells use heparanase to access IL-2 bound to extracellular matrix in inflamed tissue

  • Hunter A. Martinez,
  • Ievgen Koliesnik,
  • Gernot Kaber,
  • Jacqueline K. Reid,
  • Nadine Nagy,
  • Graham Barlow,
  • Ben A. Falk,
  • Carlos O. Medina,
  • Aviv Hargil,
  • Svenja Zihsler,
  • Israel Vlodavsky,
  • Jin-Ping Li,
  • Magdiel Pérez-Cruz,
  • Sai-Wen Tang,
  • Everett H. Meyer,
  • Lucile E. Wrenshall,
  • James D. Lord,
  • K. Christopher Garcia,
  • Theo D. Palmer,
  • Lawrence Steinman,
  • Gerald T. Nepom,
  • Thomas N. Wight,
  • Paul L. Bollyky,
  • Hedwich F. Kuipers

DOI
https://doi.org/10.1038/s41467-024-45012-9
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Although FOXP3+ regulatory T cells (Treg) depend on IL-2 produced by other cells for their survival and function, the levels of IL-2 in inflamed tissue are low, making it unclear how Treg access this critical resource. Here, we show that Treg use heparanase (HPSE) to access IL-2 sequestered by heparan sulfate (HS) within the extracellular matrix (ECM) of inflamed central nervous system tissue. HPSE expression distinguishes human and murine Treg from conventional T cells and is regulated by the availability of IL-2. HPSE-/- Treg have impaired stability and function in vivo, including in the experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis. Conversely, endowing monoclonal antibody-directed chimeric antigen receptor (mAbCAR) Treg with HPSE enhances their ability to access HS-sequestered IL-2 and their ability to suppress neuroinflammation in vivo. Together, these data identify a role for HPSE and the ECM in immune tolerance, providing new avenues for improving Treg-based therapy of autoimmunity.